The FDA has approved a CSF1 small molecule inhibitor for certain patients with symptomatic tenosynovial giant cell tumor. The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza) for the treatment of adult...
The FDA has approved the antibody-drug conjugate brentuximab vedotin, plus lenalidomide and rituximab, for certain cases of pretreated large B-cell lymphoma. The U.S. Food and Drug Administration (FDA) has approved brentuximab vedotin (Adcetris), in...
The FDA has approved a new MEK inhibitor for certain patients with symptomatic neurofibromatosis type 1. The U.S. Food and Drug Administration (FDA) has approved mirdametinib (Gomekli) for the treatment of patients with neurofibromatosis...
The FDA has approved fam-trastuzumab deruxtecan-nxki for certain HER2-low or HER2-ultralow breast cancers. The U.S. Food and Drug Administration (FDA) has approved fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) for the treatment of unresectable or metastatic, hormone...
The FDA approved treosulfan and fludarabin for patients with hematologic disorders prior to stem cell transplantation. The U.S. Food and Drug Administration (FDA) has approved treosulfan (Grafapex) with fludarabine for people with acute...
The FDA has issued its first approval for datopotamab deruxtecan-dlnk, a targeted therapy, for certain types of breast cancer. The U.S. Food and Drug Administration (FDA) has approved datopotamab deruxtecan-dlnk (dato-DXd; Datroway) for the...
The FDA approved sotorasib and panitumumab for metastatic colorectal cancer with the KRAS G12C mutation. The U.S. Food and Drug Administration (FDA) approved sotorasib (Lumakras) in combination with panitumumab (Vectibix) for the treatment of...
Acalabrutinib was granted traditional approval as a monotherapy for previously treated MCL and as part of a combination for untreated MCL. The U.S. Food and Drug Administration (FDA) has granted traditional approval to acalabrutinib...
The FDA approved nivolumab and hyaluronidase-nvhy as an injectable therapy for multiple tumor types. The U.S. Food and Drug Administration (FDA) has approved nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) for subcutaneous (under the skin) injection...
The FDA approved the kinase inhibitors encorafenib and cetuximab plus chemotherapy for the treatment of certain colorectal cancers. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to encorafenib (Braftovi), in combination...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now